Merck announced that it had entered an agreement to acquire Prometheus Biosciences.
Merck aims to strengthen its immunology portfolio through this acquisition by adding a potential first-in-class therapy for inflammatory bowel disease (IBD) and other immunological conditions.
Also read: Top pharmaceutical companies of 2023
Merck will acquire by paying $200 per share; the acquisition is expected to cost $10.8 billion. Prometheus Biosciences' lead candidate, PRA023, is a monoclonal antibody that targets the tumor necrosis factor (TNF)-like ligand 1A (TL1A), a key mediator of inflammation in IBD. The acquisition is expected to complete by the third quarter of 2023.
Also read: China Drug Approvals
Pfizer and Seagen have announced an agreement under which Pfizer will acquire Seagen for $229 in cash per share, valued at nearly $43 billion.
Pfizer is aiming that Seagen's expertise in Antibody-Drug Conjugates (ADCs) can strengthen Pfizer's oncology portfolio. Further, it is estimated that Seagen will add $10 billion in revenues by 2030. In 2023, the expected revenues from Seagen were $2.2 billion. Pfizer Oncology's portfolio has 24 approved therapies generating $12.1 billion in revenues.
Seagen's currently approved therapies include Adcetris, Padcev, Tivdak, and Tukysa. It further has eleven new molecular entities in the pipeline.
Also read: Pharmaceutical deals and acquisitions
Sanofi has announced its intention to acquire Provention Bio, a U.S.-based biopharmaceutical company, for $2.9 billion. The acquisition will add Provention Bio's first-in-class therapy in type 1 diabetes, Tzield (teplizumab), to Sanofi's portfolio. Tzield was approved in the US last year as the first and only therapy to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients aged eight years and older with stage 2 T1D.
Also read: Drug approvals in Europe
Sanofi's stated that the acquisition of Provention Bio aligns with the company's strategic shift towards developing products that have a unique profile in treating immune-mediated diseases and disease-modifying therapies, especially in areas with high unmet needs. Additionally, the acquisition is consistent with Sanofi's expertise in diabetes.
Sanofi announced that it would commence a cash tender offer to acquire Provention Bio's shares for $25.0 per share in cash, valued at approximately 2.9 billion.
With the acquisition, AstraZeneca will get access to aldosterone synthase inhibitor baxdrostat.
Baxdrostat is in Phase 2 for hyperaldosteronism and hypertension.
AstraZeneca announced that it would acquire a US-based clinical-stage biopharmaceutical company, CinCor Pharma, developing novel treatments for resistant and uncontrolled hypertension and chronic kidney disease.
With the acquisition, AstraZeneca aims to strengthen its cardiorenal portfolio with baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for resistant hypertension.
Also read: HAS Assessment outcomes
For this acquisition, AstraZeneca offered to pay $26 per share, followed by $10 per share upon successful regulatory submission of baxdrostat. The upfront payment represents a value of $1.3 billion. With the regulatory submission, the transaction value can reach $1.8 billion.